Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 10 | Mind Blowing Facts

Unemployed to be given weight-loss jags as part of UK plan to 'get them back to work'

THE Health Secretary has said unemployed people will be given weight-loss injections as part of a UK Government drive to “get them back to…

The National (Scotland)

Meet the 9 CFOs on Fortune’s 2024 Most Powerful Women list

Meet the 9 CFOs on Fortune’s 2024 Most Powerful Women list

The list of 100 executives spans the globe.

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Eli Lilly's new CFO is a 23-year company veteran—showing how pharma firms rely on a 'deep bench of qualified talent'

Lucas Montarce's career path at the company is similar to that of his predecessor, Anat Ashkenazi.

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

International Business Times

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

Eli Lilly has recently outperformed the general drug manufacturers industry, and analysts are highly optimistic about the stock’s prospects.

inkl

Read news from The Economist, FT, and more,
with one subscription

Former Maryland Resident Sentenced For Congressional Office Harassment

Former Maryland Resident Sentenced For Congressional Office Harassment

Former Maryland resident sentenced to prison for making threatening calls to congressional offices, highlighting the seriousness of threats against elected...

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

A former Maryland resident has been sentenced to more than one year behind bars for making thousands of threatening and harassing telephone calls to dozens of congressional offices across the country

The Independent UK

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

Eli Lilly Launches Discount Anti-Obesity Drug

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

International Business Times

Weight loss drug Tirzepatide cuts diabetes risk by an astonishing 94%, says study

Weight loss drug Tirzepatide cuts diabetes risk by an astonishing 94%, says study

A new study on the popular weight loss drug Tirzepatide, manufactured by American pharmaceutical company Eli Lilly, has found the drug could dramatically cut the risk of developing type 2 diabetes in obese or overweight people with prediabetes, compared with a placebo.

The Times of India

Up 58% YTD, is Eli Lilly Stock Still a Buy?

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

1 Billionaire-Backed Penny Stock With 421% Upside

1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

Get all your
news in one place.

100's of premium titles.
One news app.

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Should You Buy These Stocks Before They Join The $1 Trillion Market Cap Club?

Their strong fundamentals, brand strength, and drive to succeed could propel their stock higher.

International Business Times UK

Jim Cramer Names Six Companies That May Enter the Trillion-Dollar Stock Club

In a recent episode of CNBC's Mad Money show, Jim Cramer named companies like Eli Lilly, Tesla, JPMorgan, and Walmart that could reach a $1 trillion market valuation.

NBCU to Offer First-Ever Commercial-Free Hour During Live Coverage of the Olympics Opening Ceremony

The commercial-free hour, which begins at 1:30 p.m. ET on July 26, is sponsored by Coke, Delta, Eli Lilly, Toyota, Visa, and Xfinity

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Independent UK

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

The Independent UK

A weight loss miracle! New shot does better than Ozempic and Wegovy during trials

Tirzepatide, which is sold under the brand names Mounjaro and Zepbound – which treat diabetes and weight loss, respectively – leads to more weight loss than semaglutide, new research has shown

What Is Kisunla? Know All About New FDA-Approved Drug For Alzheimer's Disease

Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.

FDA Approves New Alzheimer's Drug To Slow Disease Progression

FDA approves Eli Lilly's donanemab for early Alzheimer's, offering hope for patients and caregivers. Treatment priced at 5 per vial.

The Guardian - US

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

The Independent UK

FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Associated Press

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

388,322 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play